Short and long term immunosuppressive effects of clozapine and haloperidol

Immunopharmacology

Volumn 37, Issue 1, 1997, Pages 75-86

  Leykin, I ^a   Mayer, R ^b   Shinitzky, M ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b Neurogenic   (Israel)

Author keywords

Immunosuppression; Neuroleptics; Schizophrenia

Indexed keywords

CLOZAPINE; CYTOKINE; GAMMA INTERFERON; HALOPERIDOL; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; INTERLEUKIN 4; MEMBRANE RECEPTOR; NEUROLEPTIC AGENT; PHYTOHEMAGGLUTININ; RADIOISOTOPE; THYMIDINE;

ADULT; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG RECEPTOR BINDING; DRUG THERAPY; ETIOLOGY; FEMALE; HUMAN; HUMAN CELL; HYPOTHESIS; LONG TERM CARE; LYMPHOCYTE PROLIFERATION; MALE; MIXED LYMPHOCYTE REACTION; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; AGED; ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; HALOPERIDOL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MIDDLE AGED; SCHIZOPHRENIA; TIME FACTORS;

EID: 0030872320     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(97)00037-4     Document Type: Article

References (61)

1. Abrams, J.S., Roncarolo, M.G., Yssel, H., Andersson, U., Gleich, G.J., Silver, J.E., 1992. Strategies of anti-cytokine monoclonal antibody development: Immunoassay of IL-10 and IL-5 in clinical samples. Immunol. Rev. 127, 5-24.
2. Adams, D.D., 1969. A theory of pathogenesis of rheumatic fever, glomerulonephritis and other autoimmune diseases triggered by infection. Clin. Exp. Immunol. 5, 105-115.
3. Adams, D.D., Knight, J.G., 1980. H gene theory of inherited autoimmune disease. Lancet i, 3986-398.
4. Baker, G.A., Santalo, R., Blumenstein, J., 1977. Effects of psychotropic agents upon the blastogenic response of human T-lymphocytes. Biol. Psychiatr. 12, 159-169.
5. Beresford, R., Ward, A., 1987. Haloperidol decanoate: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs 33, 31-49.
6. 2 dopaminergic antagonists on mouse T and B lymphocyte proliferation and interleukin production in vitro. Immunopharmacol. Immunotoxicol. 10, 501-512.
7. Centorrino, F.C., Baldessarni, R.J., Kando, J.C., Frankenburg, F.R., Volpicelli, S.A., Flood, J.G., 1994. Clozapine and metabolites: concentrations in serum and clinical findings during the treatment of chronically psychotic patients. J. Clin. Psychopharmacol. 14, 119-125.
8. Chengappa, K.N., Ganguli, R., Yang, Z.W., Shurin, G., Brar, J.S., Rabin, B.S., 1995. Impaired mitogen (PHA) responsiveness and increased autoantibodies in Caucasian schizophrenic patients with the HLA B8/DR3 phenotype. Biol. Psychiatr. 37, 546-549.
9. Coffey, C.E., Sullivan, J.L., Rice, J.R., 1983. T lymphocytes in schizophrenia. Biol. Psychiatr. 18, 113-119.
10. Creese, I., Burt, D.R., Snyder, S.H., 1976. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192, 481-483.
11. Davis, J.M., Schaffer, C.B., Killian, G.A., Kinard, C., Chan, C., 1980. Important issues in the drug treatment of schizophrenia. Schizophr. Bull. 6, 70-87.
12. DeLisi, L.E., King, A.C., Targum, S., 1985. Serum immunoglobulin concentrations in patients admitted to an acute psychiatric in-patient service. Br. J. Psychiatr. 145, 661-665.
13. Descotes, J., Evreux, J.C.L., 1981. Depressant effects of major tranquillizers on contact hypersensitivity to picryl chloride in the mouse. Experientia 37, 1004-1005.
14. Fischer-Coruelssen, K.A., Ferner, U.J., 1976. An example of European multicenter trials: multispectral analysis of clozapine. Psychopharmacol. Bull. 12, 34-39.
15. Fitton, A., Heel, R.C., 1990. Clozapine: a review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40, 722-747.
16. Freed, W.J., 1988. The therapeutic latency of neuroleptic drugs and nonspecific postjunctional supersensitivity. Schizophr. Bull. 14, 269-277.
17. Ganguli, R., Rabin, B.S., Kelly, R.H., Lyte, M., Ragu, U., 1987. Clinical and laboratory evidence of autoimmunity in acute schizophrenia. Ann. NY Acad. Sci. USA 496, 676-685.
18. Ganguli, R., Rabin, B.S., 1989. Increased serum interleukin-2 receptor concentration in schizophrenic and brain-damaged subjects. Arch. Gen. Psychiatr. 46, 292.
19. Ganguli, R., Rabin, B.S., Belle, S.H., 1989. Decreased interleukin-2 production in schizophrenic patients. Biol. Psychiatr. 26, 427-430.
20. Ganguli, R., Brar, J.S., Solomon, W., Chengappa, K.N., Rabin, B.S., 1992. Altered interleukin-2 production in schizophrenia: association between clinical state and autoantibody production. Psychiatr. Res. 44, 113-123.
21. Ganguli, R., Brar, J.S., Chengappa, K.R., DeLeo, M., Yang, Z.W., Shurin, G., Rabin, B.S., 1995. Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms. Arch. Gen. Psychiatr. 52, 668-672.
22. Gladhorn, J., Honigfeld, G., Abuzzahab, F.S., Wang, R., Steinbook, R., Tuason, V., Klerman, G., 1987. The risk and benefits of clozapine versus chlorpromazine. J. Clin. Psychopharmacol. 7, 377-384.
23. Hasegava, M., Gutierrez-Esteinou, R., Way, L., Meltzer, H.Y., 1993. Relationship between clinical efficacy and clozapine concentration in plasma in schizophrenia: effect of smoking. J. Clin. Psychopharmacol. 13, 389-390.
24. Heath, R.G., McCarron, K.L., O'Neil, C.E., 1989. Antiseptal brain antibody in IgG of schizophrenic patients. Biol. Psychiatr. 25, 725-733.
25. Henneberg, A.E., Horter, S., Ruffert, S., 1994. Increased prevalence of antibrain antibodies in the sera from schizophrenic patients. Schizophr. Res. 14, 15-22.
26. Janicki, C.A., Ko, C.Y., In: Florey, K. (Ed.), Analytical Problems of Drug Substances. Vol. 9. Academic Press, New York, 1980, pp. 341-369.
27. Kane, J., Honigfeld, G., Singer, J., Meltzer, H., 1988. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatr. 45, 789-796.
28. Kessler, S., 1980. The genetics of schizophrenia. Schizophr. Bull. 6, 404-416.
29. Knight, J.G., 1984. Is schizophrenia an autoimmune disease? A review. Methods Find. Exp. Clin. Pharmacol. 6 (7), 394-403.
30. Knight, J.G., Adams, D.D., 1982. The genetic basis of autoimmune disease. Ciba Foundation Symposium 90, 35-56.
31. Knight, J.G., Knight, A., Menkes, D.B., Mullen, P.E., 1990. Autoantibodies against brain septal region antigen specific to unmedicated schizophrenia?. Biol. Psychiatr. 28, 467-474.
32. Lane, H.Y., Lin, H.N., Hwu, H.G., Jann, M., Hu, W.H., Chang, W.H., 1995. Haloperidol plasma concentrations in Taiwanese psychiatric patients. J. Formos Med. Assoc. 94, 671-678.
33. Leon, C.A., 1979. Therapeutic effects of clozapine: a 4-year follow-up of a controlled clinical trial. Acta Psychiatr. Scand. 59, 471-480.
34. Levine, J., Susnovski, M., Handzel, Z.T., Leykin, I., Shinitzky, M., 1994. Treatment of schizophrenia with an immunosuppressant. Lancet 34, 59-60.
35. Maes, M., Bosmans, E., Calabrese, J., Smith, R., Meltzer, H.Y., 1995. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 29 (2), 141-152.
36. Maes, M., Meltzer, H.Y., Bosmans, E., 1994. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr. Scand. 89, 346-351.
37. Masserini, C., Vita, A., Basile, R., Morselli, R., Boato, P., Peruzzi, C., Pugnetti, L., Ferrante, P., Cazzullo, C.L., 1990. Lymphocyte subsets in schizophrenic disorders. Relationships with clinical, neuromorphological and treatment variables. Schizophr. Res. 3, 269-275.
38. Meltzer, H.Y., Stahl, S.M., 1976. The dopamine hypothesis of schizophrenia: a review. Schizophr. Bull. 2, 1976.
39. Nahas, G.G., Desoize, B., Leger, C., 1979. Effects of psychotropic drugs on DNA synthesis in cultured lymphocytes. Proc. Soc. Exp. Biol. Med. 160, 344-348.
40. Noy, S., Achiron, A., Laor, N., 1994. Schizophrenia and autoimmunity: A possible etiological mechanism?. Neuropsychobiology 30, 157-159.
41. Nyland, H., Naess, A., Lunde, H., 1980. Lymphocyte subpopulations in peripheral blood from schizophrenic patients. Acta Psychiatr. Scand. 61, 313-318.
42. Pandey, R.S., Gupta, A.K., Chaturvedi, U.C., 1981. Autoimmune model of schizophrenia with special reference to antibrain antibodies. Biol. Psychiatr. 16, 1123-1136.
43. Peroutka, S.J., Snyder, S.H., 1980. Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic and histamine receptors to clinical potency. Am. J. Psychiatr. 137, 1518-1522.
44. Pert, C.B., Knight, J.G., Laing, P., Markwell, M.A.K., 1988. Scenarios for a viral etiology of schizophrenia. Schizophr. Bull. 14 (2), 243-247.
45. Pickar, D., Owen, R.R., Litman, R.E., Konicki, P.E., Gutierrez, R., Rapaport, M.H., 1992. Clinical and biological response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch. Gen. Psychiatr. 49, 345-353.
46. 51Cr release assay of clozapine-induced cytotoxicity: evidence for immunogenetic mechanism. J. Clin. Psychiatr. 55 (9, Suppl B), 143-148.
47. Rapaport, M.H., McAllister, C.G., Kirch, D.G., Pickar, D., 1990. The effect of typical and atypical neuroleptics on mitogen-induced T lymphocyte responsiveness. Biol. Psychiatr. 29, 715-717.
48. Richelson, E., 1984. Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J. Clin. Psychiatr. 45, 331-336.
49. Roberts, D.F., Kinnell, H.G., 1981. Immunogenetics and schizophrenia. Psychol. Med. 11, 441-447.
50. Schleuning, M.J., Duggan, A., Reem, G.H., 1989. Inhibition by chlorpromazine of lymphokine-specific mRNA expression in human thymocytes. Eur. J. Immunol. 19, 1491-1496.
51. 2 in schizophrenia: role of endogenous dopamine and cerebellum. Neuropsychopharmacology 7, 55-57.
52. Shintani, F., Kanba, S., Maruo, N., Nakaki, T., Nibuya, M., Suzuki, E., Kinoshita, N., Yagi, G., 1991. Serum interleukin-6 level in schizophrenic patients. Life Sci. 49, 661-664.
53. Shopsin, B., Klein, H., Aaronson, M., Collora, M., 1979. Clozapine, chlorpromazine and placebo in newly hospitalized acutely schizophrenic patients. Arch. Gen. Psychiatr. 36, 657-664.
54. Snyder, S.H., 1976. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am. J. Psychiatr. 133, 197-202.
55. Stater E., Cowie V. The genetics of mental disorders. University Press, London, Oxford, 1971.
56. Sugerman, A.A., Southern, D.L., Curran, J.F., 1982. A study of antibody levels in alcoholic, depressive and schizophrenic patients. Ann. Allerg. 48, 166.
57. Ulrich, S., Meyer, F.P., Neuhof, S., Knorr, W., 1995. Megabore capillary gas-liquid chromatographic method with nitrogen-phosphorus selective detection for the assay of haloperidol and reduced haloperidol in serum: results of therapeutic drug-monitoring during acute therapy of eight schizophrenics. J. Chromatogr. B. Biomed. Appl. 663, 289-296.
58. Van Praag, H.M., Korf, J., Dois, L.C.W., 1976. Clozapine versus perphenazine: the value of the biochemical mode of action of neuroleptics in predicting their therapeutic efficacy. Br. J. Psychiatr. 129, 547-555.
59. Vartanyan, M.E., Kolyaskina, G.I., Lozovsky, O.V., Burbaeva, G.Sh., Ignatov, S.A., 1978. Aspects of humoral and cellular immunity in schizophrenia. Birth Defects 14, 339-364.
60. Wilke, I., Arolt, V., Rothermundt, M., Weitzsch, Ch., Hornberg, M., Kirchner, H., 1996. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur. Arch. Psychiatr. Clin. Neurosci. 246, 279-284.
61. Yang, Z.W., Chengappa, K.N., Shurin, G., Brar, J.S., Rabin, B.S., Gubbi, A.V., Ganguli, R., 1994. An association between anti-hippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia. Psychol. Med. 24, 449-455.